868 related articles for article (PubMed ID: 21460794)
1. The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases.
Chowdhury R; Yeoh KK; Tian YM; Hillringhaus L; Bagg EA; Rose NR; Leung IK; Li XS; Woon EC; Yang M; McDonough MA; King ON; Clifton IJ; Klose RJ; Claridge TD; Ratcliffe PJ; Schofield CJ; Kawamura A
EMBO Rep; 2011 May; 12(5):463-9. PubMed ID: 21460794
[TBL] [Abstract][Full Text] [Related]
2. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases.
Xu W; Yang H; Liu Y; Yang Y; Wang P; Kim SH; Ito S; Yang C; Wang P; Xiao MT; Liu LX; Jiang WQ; Liu J; Zhang JY; Wang B; Frye S; Zhang Y; Xu YH; Lei QY; Guan KL; Zhao SM; Xiong Y
Cancer Cell; 2011 Jan; 19(1):17-30. PubMed ID: 21251613
[TBL] [Abstract][Full Text] [Related]
3. What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer.
Losman JA; Kaelin WG
Genes Dev; 2013 Apr; 27(8):836-52. PubMed ID: 23630074
[TBL] [Abstract][Full Text] [Related]
4. (R)-2-Hydroxyglutarate Inhibits KDM5 Histone Lysine Demethylases to Drive Transformation in IDH-Mutant Cancers.
Gunn K; Myllykoski M; Cao JZ; Ahmed M; Huang B; Rouaisnel B; Diplas BH; Levitt MM; Looper R; Doench JG; Ligon KL; Kornblum HI; McBrayer SK; Yan H; Duy C; Godley LA; Koivunen P; Losman JA
Cancer Discov; 2023 Jun; 13(6):1478-1497. PubMed ID: 36847506
[TBL] [Abstract][Full Text] [Related]
5. (R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible.
Losman JA; Looper RE; Koivunen P; Lee S; Schneider RK; McMahon C; Cowley GS; Root DE; Ebert BL; Kaelin WG
Science; 2013 Mar; 339(6127):1621-5. PubMed ID: 23393090
[TBL] [Abstract][Full Text] [Related]
6. Studies on the Interaction of the Histone Demethylase KDM5B with Tricarboxylic Acid Cycle Intermediates.
Tarhonskaya H; Nowak RP; Johansson C; Szykowska A; Tumber A; Hancock RL; Lang P; Flashman E; Oppermann U; Schofield CJ; Kawamura A
J Mol Biol; 2017 Sep; 429(19):2895-2906. PubMed ID: 28827149
[TBL] [Abstract][Full Text] [Related]
7. IDH mutation impairs histone demethylation and results in a block to cell differentiation.
Lu C; Ward PS; Kapoor GS; Rohle D; Turcan S; Abdel-Wahab O; Edwards CR; Khanin R; Figueroa ME; Melnick A; Wellen KE; O'Rourke DM; Berger SL; Chan TA; Levine RL; Mellinghoff IK; Thompson CB
Nature; 2012 Feb; 483(7390):474-8. PubMed ID: 22343901
[TBL] [Abstract][Full Text] [Related]
8. The cancer driver genes IDH1/2, JARID1C/ KDM5C, and UTX/ KDM6A: crosstalk between histone demethylation and hypoxic reprogramming in cancer metabolism.
Chang S; Yim S; Park H
Exp Mol Med; 2019 Jun; 51(6):1-17. PubMed ID: 31221981
[TBL] [Abstract][Full Text] [Related]
9. [(R)-2-hydroxyglutarate or (R)-2HG is an oncometabolite].
Larsen CJ
Bull Cancer; 2013; 100(7-8):655. PubMed ID: 24063024
[No Abstract] [Full Text] [Related]
10. Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation.
Koivunen P; Lee S; Duncan CG; Lopez G; Lu G; Ramkissoon S; Losman JA; Joensuu P; Bergmann U; Gross S; Travins J; Weiss S; Looper R; Ligon KL; Verhaak RG; Yan H; Kaelin WG
Nature; 2012 Feb; 483(7390):484-8. PubMed ID: 22343896
[TBL] [Abstract][Full Text] [Related]
11. Hypoxia Induces Production of L-2-Hydroxyglutarate.
Intlekofer AM; Dematteo RG; Venneti S; Finley LW; Lu C; Judkins AR; Rustenburg AS; Grinaway PB; Chodera JD; Cross JR; Thompson CB
Cell Metab; 2015 Aug; 22(2):304-11. PubMed ID: 26212717
[TBL] [Abstract][Full Text] [Related]
12. Isocitrate dehydrogenase mutation as a therapeutic target in gliomas.
Han CH; Batchelor TT
Chin Clin Oncol; 2017 Jun; 6(3):33. PubMed ID: 28705010
[TBL] [Abstract][Full Text] [Related]
13. Isocitrate Dehydrogenase Mutations in Cancer: Mechanisms of Transformation and Metabolic Liability.
Gunn K; Losman JA
Cold Spring Harb Perspect Med; 2024 May; 14(5):. PubMed ID: 38191174
[TBL] [Abstract][Full Text] [Related]
14. Oncometabolite D-2-Hydroxyglutarate enhances gene silencing through inhibition of specific H3K36 histone demethylases.
Janke R; Iavarone AT; Rine J
Elife; 2017 Mar; 6():. PubMed ID: 28346139
[TBL] [Abstract][Full Text] [Related]
15. 2-Hydroxyglutarate in Cancer Cells.
Ježek P
Antioxid Redox Signal; 2020 Nov; 33(13):903-926. PubMed ID: 31847543
[No Abstract] [Full Text] [Related]
16. The role of metabolic enzymes in mesenchymal tumors and tumor syndromes: genetics, pathology, and molecular mechanisms.
Schaefer IM; Hornick JL; Bovée JVMG
Lab Invest; 2018 Apr; 98(4):414-426. PubMed ID: 29339836
[TBL] [Abstract][Full Text] [Related]
17. The oncometabolite 2-hydroxyglutarate activates the mTOR signalling pathway.
Carbonneau M; M Gagné L; Lalonde ME; Germain MA; Motorina A; Guiot MC; Secco B; Vincent EE; Tumber A; Hulea L; Bergeman J; Oppermann U; Jones RG; Laplante M; Topisirovic I; Petrecca K; Huot MÉ; Mallette FA
Nat Commun; 2016 Sep; 7():12700. PubMed ID: 27624942
[TBL] [Abstract][Full Text] [Related]
18. IDH1 and IDH2 mutations in tumorigenesis: mechanistic insights and clinical perspectives.
Yang H; Ye D; Guan KL; Xiong Y
Clin Cancer Res; 2012 Oct; 18(20):5562-71. PubMed ID: 23071358
[TBL] [Abstract][Full Text] [Related]
19. Reductive carboxylation and 2-hydroxyglutarate formation by wild-type IDH2 in breast carcinoma cells.
Smolková K; Dvořák A; Zelenka J; Vítek L; Ježek P
Int J Biochem Cell Biol; 2015 Aug; 65():125-33. PubMed ID: 26007236
[TBL] [Abstract][Full Text] [Related]
20. Identification of additional IDH mutations associated with oncometabolite R(-)-2-hydroxyglutarate production.
Ward PS; Cross JR; Lu C; Weigert O; Abel-Wahab O; Levine RL; Weinstock DM; Sharp KA; Thompson CB
Oncogene; 2012 May; 31(19):2491-8. PubMed ID: 21996744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
